melior discovery

About Us
Our Pipeline
Our Platform
Partnering with Us
News
Contact Us

Click here for the MLR-1023 non-confidential brochure          

melior melior discovery

Our Platform discovery strategy

Uniquely Productive Drug Discovery Strategy

The theraTRACE® indications discovery platform allows for known drug-like compounds to be comprehensively screened using a battery of in vivo assays spanning multiple therapeutic areas. Currently over 40 validated animal models are represented in the platform spanning a broad range of therapeutic areas including inflammation, immunology, diabetes & metabolic syndrome, dermatology, cardiovascular, gastrointestinal, psychiatric, neurological and neurodegenerative disorders.

 

The in vivo models utilized in the theraTRACE® platform comprise those typically used by pharmaceutical companies to determine whether a drug candidate is suitable for further clinical evaluation, however, these models are assembled in a proprietary “multiplexed” format that allows drug discoverers to evaluate a compound for potential efficacy in a broad array of therapeutic areas rapidly and cost-effectively. In most cases, Melior’s theraTRACE® system is able to provide a complete pharmacological fingerprint/profile of a compound in 10 weeks. Melior’s theraTRACE® system has found particular utility in facilitating the crucial “go/no go” development decisions routinely faced by pharmaceutical and biopharmaceutical companies.

Visit Melior Discovery to learn more about the cost-effective, efficient and systematic theraTRACE® indications discovery platform.

 

 

If you are interested in learning more about our Discovery Strategy, please contact bizdev@meliordiscovery.com to start the conversation.

Back to top of page

 
home